세계 동반진단(CDx) 시장 규모는 2034년까지 연평균 11% 성장할 것으로 예상됩니다.
CDx 시장은 주로 기술 개발의 혜택을 받아 확대되고 있습니다. 이러한 개발로 인해 더 우수하고, 더 민감하고, 더 집중적인 CDx 검사가 탄생하고 있습니다. 차세대 염기서열 분석(NGS), 액체 생검, AI와 같은 기술의 발전은 CDx 산업에 큰 영향을 미치고 있으며, 향후 몇 년동안 시장 확대를 촉진할 것으로 예상됩니다. 개인 맞춤형 의료에서 점점 더 중요한 역할을 하고 있습니다.
세계의 동반진단(CDx) 시장을 조사했으며, 시장 개요, 시장 성장에 영향을 미치는 요인 및 시장 기회 분석, 시장 규모 추이 및 예측, 각 부문별/지역별 상세 분석, 경쟁 구도, 주요 기업 개요 등의 정보를 정리하여 전해드립니다.
목차
제1장 보고서 개요
제2장 주요 요약
제3장 시장 개요
주요 조사 결과
시장 역학
시장 성장 촉진요인
시장 성장 억제요인
시장 기회
COVID-19의 영향 분석
Porter의 Five Forces 분석
PEST 분석
제4장 동반진단(CDx) 시장 분석 : 제품 및 서비스별
주요 조사 결과
시장의 매력 지수
시장 규모 추이와 예측
어세이 및 키트/시약
소프트웨어 및 서비스
시장 규모 추이와 예측 : 지역별
시장 점유율 : 지역별
제5장 동반진단(CDx) 시장 분석 : 적응증별
주요 조사 결과
시장의 매력 지수
시장 규모 추이와 예측
암
감염증
심혈관 질환
신경 질환
기타
시장 규모 추이와 예측 : 지역별
시장 점유율 : 지역별
제6장 동반진단(CDx) 시장 분석 : 기술별
주요 조사 결과
시장의 매력 지수
시장 규모 추이와 예측
중합효소 연쇄반응(PCR)
차세대 시퀀싱(NGS)
In Situ Hybridazation(ISH)
면역조직화학(IHC) 0
기타 기술
시장 규모 추이와 예측 : 지역별
시장 점유율 : 지역별
제7장 동반진단(CDx) 시장 분석 : 최종사용자별
주요 조사 결과
시장의 매력 지수
시장 규모 추이와 예측
제약 및 바이오의약품 기업
참조 실험실
수탁 연구기관(CRO)
기타
시장 규모 추이와 예측 : 지역별
시장 점유율 : 지역별
제8장 동반진단(CDx) 시장 분석 : 지역별
주요 조사 결과
시장 규모 추이와 예측
제9장 북미의 동반진단(CDx) 시장 분석
제10장 유럽의 동반진단(CDx) 시장 분석
제11장 아시아태평양의 동반진단(CDx) 시장 분석
제12장 라틴아메리카의 동반진단(CDx) 시장 분석
제13장 중동 및 아프리카의 동반진단(CDx) 시장 분석
제14장 기업 개요
전략적 전망
F. Hoffmann-La Roche Ltd
Agilent Technologies, Inc.
QIAGEN
Thermo Fisher Scientific Inc.
Abbott
Almac Group
Danaher Corporation
Illumina, Inc.
bioMerieux
Myriad Genetics, Inc.
Sysmex Corporation
Guardant Health
제15장 결론 및 추천 사항
Visiongain의 결론
참여 기업을 위한 추천 사항
LSH
영문 목차
영문목차
The global Companion Diagnostics (CDx) market is projected to grow at a CAGR of 11% by 2034.
“The Companion Diagnostics (CDx) Market Report 2024-2034”: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to understand the industry and its underlying dynamics better. It will be useful for companies that want to expand into different industries or their existing operations in a new region.
Technological Improvements in the CDx Market
The market for CDx is expanding thanks in large part to technological developments. Better, more sensitive, and more focused CDx tests are coming from these developments. Important technical developments in CDx include the following:
Next-generation sequencing (NGS): Entire tumour genomes can be sequenced using NGS, a high-throughput sequencing technology. This data can be used to pinpoint genetic mutations that particular medications can target.
Liquid biopsy: A less intrusive procedure that can identify cancer cells and other indicators in the circulation is liquid biopsy. This test can be used to track the course of cancer and the effectiveness of treatment and is less intrusive than conventional tissue biopsies.
AI (artificial intelligence): AI is being used to create computer algorithms capable of analysing enormous amounts of CDx data. This information can be utilised to spot patterns and forecast patient outcomes.
These technological improvements are having a significant impact on the CDx industry and are projected to fuel market expansion in the coming years. CDx tests are getting more accurate, sensitive, and inexpensive as a result of these improvements, and they are playing an increasingly essential role in personalised medicine.
In 2023, a number of significant businesses plan to make significant investments in companion diagnostics. Here are few instances:
Roche: With a strong emphasis on cancer, Roche is a prominent player in the companion diagnostics (CDx) market. The business has created a number of complementary diagnostics for its targeted cancer treatments, including Zelboraf and Herceptin.
Another significant participant in the companion diagnostics business is Abbott Laboratories. The Clariscan companion diagnostic test from the company assists in forecasting a patient's reaction to the chemotherapy medication irinotecan.
Thermo Fisher Scientific: This top supplier of tools and supplies for companion diagnostic testing is Thermo Fisher Scientific. Several firms are developing companion diagnostic tests using the company's Ion Torrent NGS platform.
Hence, these improvements and new product introductions highlight the CDx market's dynamic nature and its potential to revolutionise cancer therapy by providing precision medicine.
High Capital Investment and Low Cost-benefit Ratio Likely to Challenge Industry Growth
These specialised tests require significant capital expenditure to design and validate. Companion diagnostics, in contrast to more general diagnostic instruments, serve a specific and narrower population. This indicates that the market may not be as large as expected, which would make it difficult to recover the high expenses associated with R&D and obtaining necessary permits. These tests also frequently need for advanced infrastructure and technologies, which raises the cost even further.
The development and validation of these specialised tests necessitates substantial capital commitment. Companion diagnostics, as opposed to broader diagnostic instruments, target a smaller, more specific group. As a result, the market size may be limited, making it difficult to recoup the significant expenditures of research, development, and regulatory approvals. Furthermore, these examinations frequently necessitate expensive technology and infrastructure, which increases the budgetary load.
However, calculating the cost-benefit ratio might be difficult. Companion diagnostics have the potential to improve treatment efficacy and reduce waste by ensuring that the right patients receive the proper treatment. This can result in cost reductions for healthcare systems as well as better patient outcomes. However, realising these benefits is contingent on a number of circumstances, including the prevalence of the targeted group, the efficacy of the companion medication, and the cost of the test itself.
When the target population is small or the diagnostic cost is high, the cost-benefit ratio may be skewed to the negative. Manufacturers may be discouraged from investing in companion diagnostics, even if they provide great therapeutic value.
What Questions Should You Ask Before Buying a Market Research Report?
How is the companion diagnostics (CDx) market evolving?
What is driving and restraining companion diagnostics (CDx) market?
How will each companion diagnostics (CDx) submarket segment grow over the forecast period, and how much revenue will these submarkets account for in 2034?
How will the market shares for each companion diagnostics submarket develop from 2024 to 2034?
What will be the main driver for the overall market from 2024 to 2034?
Will leading companion diagnostics (CDx) markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
How will the market shares of the national markets change by 2034, and which geographical region will lead the market in 2034?
Who are the leading players, and what are their prospects over the forecast period?
What are the companion diagnostics (CDx) projects for these leading companies?
How will the industry evolve during the period between 2024 and 2034? What are the implications of companion diagnostics projects taking place now and over the next 10 years?
Is there a greater need for product commercialization to further scale companion diagnostics (CDx) market?
Where is the companion diagnostics (CDx) market heading and how can you ensure you are at the forefront of the market?
What are the best investment options for new product and service lines?
What are the key prospects for moving companies into a new growth path and C-suite?
You need to discover how this will impact the Companion Diagnostics (CDx) Market today, and over the next 10 years:
Our 307-page report provides 100 tables and 170 charts/graphs exclusively to you.
The report highlights key lucrative areas in the industry so you can target them - NOW.
It contains in-depth analysis of global, regional and national sales and growth.
It highlights for you the key successful trends, changes and revenue projections made by your competitors.
This report tells you TODAY how the Companion Diagnostics (CDx) Market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.
Forecasts to 2034 and other analyses reveal commercial prospects
In addition to revenue forecasting to 2034, our new study provides you with recent results, growth rates, and market shares.
You will find original analyses, with business outlooks and developments.
Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising Companion Diagnostics prices and recent developments.
This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, ""V" ", "L", "W" and "U" are discussed in this report.
Segments Covered in the Report:
Product & Services
Assays, Kits & Reagents
Software & Services
Technology
Polymerase Chain Reaction (PCR)
Next-Generation Sequencing (NGS)
In Situ Hybridization (ISH)
Immunohistochemistry (IHC)
Other Technologies
Indication
Cancer
Infectious Diseases
Cardiovascular Diseases
Neurological Diseases
Other Indications
End-users
Pharmaceutical & Biopharmaceutical Companies
Reference Laboratories
Contract Research Organizations (CROs)
Other End-users
In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and the U.S., China, U.K., India, and Brazil leading national markets:
North America
U.S.
Canada
Europe
Germany
UK
France
Spain
Italy
Rest of Europe
Asia Pacific
China
Japan
India
Australia
South Korea
Rest of Asia Pacific
Latin America
Brazil
Mexico
Rest of Latin America
MEA
GCC
South Africa
Rest of MEA
The report also includes profiles and for some of the leading companies in the Companion Diagnostics (CDx) Market, 2024 to 2034, with a focus on this segment of these companies' operations.
Leading Companies profiled in the report:
Abbott
Agilent Technologies, Inc.
Almac Group
bioMerieux
Danaher Corporation
F. Hoffmann-La Roche Ltd.
Guardant Health
Illumina, Inc.
Myriad Genetics, Inc.
QIAGEN
Sysmex Corporation
Thermo Fisher Scientific Inc.
Overall world revenue for Companion Diagnostics (CDx) Market, 2024 to 2034 in terms of value the market will surpass US$6,500 million in 2024, our work calculates. We predict strong revenue growth through to 2034. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
How will the “Companion Diagnostics (CDx) Market, 2024 to 2034” report help you?
In summary, our 300+ page report provides you with the following knowledge:
Revenue forecasts to 2034 for Companion Diagnostics (CDx) Market, 2024 to 2034, with forecasts for product & services, technology, indication, and end-users each forecast at a global and regional level - discover the industry's prospects, finding the most lucrative places for investments and revenues.
Revenue forecasts to 2034 for five regional and 16 key national markets - See forecasts for the Companion Diagnostics (CDx) Market, 2024 to 2034 market in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.
Prospects for established firms and those seeking to enter the market - including company profiles for Abbott, Agilent Technologies, Inc., Almac Group, bioMerieux, Danaher Corporation, F. Hoffmann-La Roche Ltd, Guardant Health, Illumina, Myriad Genetics, Inc,, QIAGEN, Sysmex Corporation, and Thermo Fisher Scientific Inc. and other major companies involved in the Companion Diagnostics (CDx) Market.
Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.
Information found nowhere else
With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain's study is for everybody needing commercial analyses for the Companion Diagnostics (CDx) Market, 2024 to 2034, market-leading companies. You will find data, trends and predictions.
Table of Contents
1 Report Overview
1.1 Objectives of the Study
1.2 Introduction to Companion Diagnostics (CDx) Market
1.3 What This Report Delivers
1.4 Why You Should Read This Report
1.5 Key Questions Answered by This Analytical Report
1.6 Who is This Report for?
1.7 Methodology
1.7.1 Market Definitions
1.7.2 Market Evaluation & Forecasting Methodology
1.7.3 Data Validation
1.7.3.1 Primary Research
1.7.3.2 Secondary Research
1.8 Frequently Asked Questions (FAQs)
1.9 Associated Visiongain Reports
1.10 About Visiongain
2 Executive Summary
3 Market Overview
3.1 Key Findings
3.2 Market Dynamics
3.2.1 Market Driving Factors
3.2.1.1 Increasing Rate of Chronic Illnesses
3.2.1.2 Technological Improvements in the CDx Market
3.2.1.3 Increasing Public Awareness of Personalised Medicine
3.2.1.4 Growing Need for Targeted Therapy
3.2.1.5 Rising Importance of Personalized Medicine
3.2.1.6 Increasing Global Incidence of Cancer
3.2.1.7 Growing Application Areas of Companion Diagnostics
3.2.2 Market Restraining Factors
3.2.2.1 Serious Issues and Substantial Medical Costs
3.2.2.2 Creating and Approving CDx Tests is a Challenging and Intricate Process.
3.2.2.3 High Capital Investment and Low Cost-benefit Ratio
3.2.2.4 Uncertain Reimbursement Scenario in Different Regions
3.2.2.5 High Cost of Immunotherapy Treatment
3.2.3 Market Opportunities
3.2.3.1 Creating New CDx Tests for Novel Targeted Medicines
3.2.3.2 Favourable Government Policies
3.2.3.3 Expansion into New Geographic Markets
3.2.3.4 Increasing Demand for Next-Generation Sequencing in CDx
3.2.3.5 Growing Significance of Companion Diagnostics in Drug Development
3.2.3.6 Higher Number of Clinical Trials
3.3 COVID-19 Impact Analysis
3.4 Porter Analysis
3.5 PEST Analysis
4 Companion Diagnostics (CDx) Market Analysis by Product & Services
4.1 Key Findings
4.2 Product & Services Segment: Market Attractiveness Index
4.3 Companion Diagnostics (CDx) Market Size Estimation and Forecast by Product & Services
4.4 Assays, Kits & Reagents
4.4.1 Market Size by Region, 2024-2034 (US$ Million)
4.4.2 Market Share by Region, 2024 & 2034 (%)
4.5 Software & Services
4.5.1 Market Size by Region, 2024-2034 (US$ Million)
4.5.2 Market Share by Region, 2024 & 2034 (%)
5 Companion Diagnostics (CDx) Market Analysis by Indication
5.1 Key Findings
5.2 Indication Segment: Market Attractiveness Index
5.3 Companion Diagnostics (CDx) Market Size Estimation and Forecast by Indication
5.4 Cancer
5.4.1 Market Size by Region, 2024-2034 (US$ Million)
5.4.2 Market Share by Region, 2024 & 2034 (%)
5.5 Infectious Disease
5.5.1 Market Size by Region, 2024-2034 (US$ Million)
5.5.2 Market Share by Region, 2024 & 2034 (%)
5.6 Cardiovascular Diseases
5.6.1 Market Size by Region, 2024-2034 (US$ Million)
5.6.2 Market Share by Region, 2024 & 2034 (%)
5.7 Neurological Diseases
5.7.1 Market Size by Region, 2024-2034 (US$ Million)
5.7.2 Market Share by Region, 2024 & 2034 (%)
5.8 Other Indications
5.8.1 Market Size by Region, 2024-2034 (US$ Million)
5.8.2 Market Share by Region, 2024 & 2034 (%)
6 Companion Diagnostics (CDx) Market Analysis by Technology
6.1 Key Findings
6.2 Technology Segment: Market Attractiveness Index
6.3 Companion Diagnostics (CDx) Market Size Estimation and Forecast by Technology
6.4 Polymerase Chain Reaction (PCR)
6.4.1 Market Size by Region, 2024-2034 (US$ Million)
6.4.2 Market Share by Region, 2024 & 2034 (%)
6.5 Next-Generation Sequencing (NGS)
6.5.1 Market Size by Region, 2024-2034 (US$ Million)
6.5.2 Market Share by Region, 2024 & 2034 (%)
6.6 In Situ Hybridization (ISH)
6.6.1 Market Size by Region, 2024-2034 (US$ Million)
6.6.2 Market Share by Region, 2024 & 2034 (%)
6.7 Immunohistochemistry (IHC)
6.7.1 Market Size by Region, 2024-2034 (US$ Million)
6.7.2 Market Share by Region, 2024 & 2034 (%)
6.8 Other Technologies
6.8.1 Market Size by Region, 2024-2034 (US$ Million)
6.8.2 Market Share by Region, 2024 & 2034 (%)
7 Companion Diagnostics (CDx) Market Analysis by End-users
7.1 Key Findings
7.2 End-users Segment: Market Attractiveness Index
7.3 Companion Diagnostics (CDx) Market Size Estimation and Forecast by End-users
7.4 Pharmaceutical & Biopharmaceutical Companies
7.4.1 Market Size by Region, 2024-2034 (US$ Million)
7.4.2 Market Share by Region, 2024 & 2034 (%)
7.5 Reference Laboratories
7.5.1 Market Size by Region, 2024-2034 (US$ Million)
7.5.2 Market Share by Region, 2024 & 2034 (%)
7.6 Contract Research Organizations (CROs)
7.6.1 Market Size by Region, 2024-2034 (US$ Million)
7.6.2 Market Share by Region, 2024 & 2034 (%)
7.7 Other End-users
7.7.1 Market Size by Region, 2024-2034 (US$ Million)
7.7.2 Market Share by Region, 2024 & 2034 (%)
8 Companion Diagnostics (CDx) Market Analysis by Region
8.1 Key Findings
8.2 Regional Market Size Estimation and Forecast
9 North America Companion Diagnostics (CDx) Market Analysis
9.1 Key Findings
9.2 North America Companion Diagnostics (CDx) Market Attractiveness Index
9.3 North America Companion Diagnostics (CDx) Market by Country, 2024, 2029 & 2034 (US$ Million)
9.4 North America Companion Diagnostics (CDx) Market Size Estimation and Forecast by Country
9.5 North America Companion Diagnostics (CDx) Market Size Estimation and Forecast by Product & Services
9.6 North America Companion Diagnostics (CDx) Market Size Estimation and Forecast by Indication
9.7 North America Companion Diagnostics (CDx) Market Size Estimation and Forecast by Technology
9.8 North America Companion Diagnostics (CDx) Market Size Estimation and Forecast by End-users
9.9 U.S. Companion Diagnostics (CDx) Market Analysis
